iL-19
View specifications and product information.
View product →PL41 lipid for research. Confirm price, batch availability and lead time by quotation.
DSPG is additionally required for the cited PL41-PG formulation and is not included in this three-component set. RNA is not included. Component quantities are sales pack sizes, not a premixed formulation.
PL41 是一种含磷酰胺结构和哌嗪基团的可电离脂质,用于研究巨噬细胞 mRNA 递送、原位 CAR-M 构建及恶性腹水中的免疫重编程。文献中的 PL41-PG LNP 含有阴离子脂质 DSPG,用于 TREM2 依赖性递送和受体降解研究。相关证据来自细胞实验、小鼠模型及人腹水样本的离体实验。本产品为 PL41 脂质原料;完整纳米颗粒的性能取决于配方、RNA 载荷及实验条件。
| CAS No. | Not available |
| Chemical Name | PL41 |
| SMILES | CCCCCCCCCCC(CCCCCCCCCC)CNCCCN1CCN(CCCNP(=O)(OCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)OCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC1 |
| Formula | C82H165N4O7P |
| M.Wt | 1350.22 |
| Purity | To be confirmed; request batch COA |
| Storage | Follow the supplied batch storage instructions; request stability and handling information. |
| Shipping condition | Contact us for current shipping conditions |
| Synonyms | PL-41; PL 41; PL41 ionizable lipid |
| Stereochemistry / form | Neutral parent as drawn; no counterion or stereochemical designation. |
| Publication | Yijia Li, Ting Yang, Xiyue Zhang et al. In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites. Nature Materials (2026). DOI: 10.1038/s41563-026-02769-2. |
最终 PL41-PG LNP 的 PL41:DSPC:胆固醇:DMG-PEG2000:DSPG 摩尔比为 45:9:34.65:1.35:10,总计 100 mol%。DSPG 为 1,2-二硬脂酰-sn-甘油-3-磷酸甘油,即文中所称的 PG。该配比描述完整实验配方,不代表 PL41 原料的组成。
证据来自临床前小鼠研究及人腹水样本的离体实验,不能作为人体临床疗效或安全性结论。PL41 是脂质原料;PL41-PG LNP、载 CAR mRNA 的 LNP 及联合治疗的结果不能直接归因于单独的 PL41,也不保证在其他配方中复现。所提供资料未确定 N/P 比或 PL41 的 pKa,不据此推算。
以下详细实验条件及引用保留英文原文术语。
文献报道的 PL41-PG 配方含有五种脂质组分。下列用量以总脂质 1 µmol 为基准,而非 PL41 1 µmol。
| 组分 | DC Chemicals 产品 | 分子量 (g/mol) | 摩尔比例 (mol%) | 总脂质为 1 µmol 时的质量 (mg) |
|---|---|---|---|---|
| PL41 | DCL0029 | 1350.22 | 45 | 0.607599 |
| DSPC | DC57005 | 790.15 | 9 | 0.071114 |
| 胆固醇 | DCD-041 | 386.65 | 34.65 | 0.133974 |
| DMG-PEG2000 | DC40169 | 2507 | 1.35 | 0.033845 |
| DSPG | 尚未唯一对应 | 未注明盐形式 | 10 | 需先确认分子量 |
文献报道的组成:PL41/DSPC/胆固醇/DMG-PEG2000/DSPG = 45:9:34.65:1.35:10 mol%(合计 100 mol%)。来源:补充表 S1,PDF 第 30 页 / 印刷页码第 29 页;正文方法部分,PDF 第 18 页。 原始论文与补充信息
质量为用于实验规划的计算值。DMG-PEG2000 采用标称平均分子量 2507 g/mol。论文未注明 DSPG 的反离子;输入分子量前,请确认所供应产品的形式。此处不推算 N/P 或 RNA 剂量。
修改总脂质量、分子量和摩尔百分比,以计算研究方案。DSPG 分子量保持空白,直至确认所供应产品的形式。计算结果并非研究实测数据;修改输入值不会改变上方引用的配方。
| 组分 | 分子量 (g/mol) | 摩尔比例 (mol%) | 质量 (mg) | 质量百分比 |
|---|---|---|---|---|
| PL41 | ||||
| DSPC | ||||
| 胆固醇 | ||||
| DMG-PEG2000 | ||||
| DSPG |
输入经确认的 DSPG 分子量并补全所有输入项,即可计算各组分质量和质量百分比。不会对缺失值作假设。
质量 (mg) = 总脂质量 (µmol) × 摩尔分数 × 分子量 (g/mol) ÷ 1000。质量百分比 = 组分质量 ÷ 各组分总质量 × 100。
Microfluidic mixing of aqueous mRNA and ethanol lipid phases at 3:1 by volume. Final mRNA concentration: 0.1 mg/mL. Dialysis overnight at 4 °C against PBS using a 12–14 kDa MWCO membrane. Total mixing flow rate, assembly buffer/pH, N/P and lipid:mRNA mass ratio were not reported in the supplied method.
Source: Methods — Preparation and characterization of LNP formulation (main PDF p. 18).
PL41-PS and PL55-PS were advanced after the healthy-mouse reporter screen (5 µg mRNA per mouse, intraperitoneal, 6 h; n = 5 per group pooled from two experiments). PL41 then gave higher membrane-bound CAR expression than PL55 in mouse BMDM-TAMs and human THP-1-derived M2 macrophages (24 h; n = 3 independent tests).
Source: Main Fig. 2d–g; Supplementary Fig. S6c,d; Methods.
The tested PL41-PS, PL41-PI and PL41-PG formulations were approximately 150–200 nm and achieved approximately 90% mRNA encapsulation. These ranges describe the tested formulations and are not specifications for neat PL41.
Source: Main text; Supplementary Fig. S6g,h.
In the ligand comparison, the 10 mol% PG formulation gave approximately eightfold higher reporter expression in wild-type than Trem2-knockout macrophages. This comparison is WT versus knockout cells, not PL41 versus ALC-0315.
Source: Main Fig. 2i; main text.
PL41-PG LNPs delivered hCLDN18.2-targeting CAR mRNA and supported macrophage reprogramming in mouse malignant-ascites models. The study also examined patient-derived ascites ex vivo. Antitumour findings depend on the RNA-loaded formulation, administration schedule, tumour model and, for combination arms, anti-PD-1 treatment.
Source: Main Figs. 3–6; Extended Data; Methods.
The study evaluated cell viability and mouse tolerability under specified experimental conditions. These preclinical observations do not establish human safety or the safety of other doses, routes or formulations.
Source: Main text and Supplementary Information.
At M.Wt 1350.22 g/mol, 100 mg = 74.06 µmol and 250 mg = 185.16 µmol. These are amount conversions for planning, not a validated LNP scale-up protocol.
Values shown are literature-reported results for the cited formulation and study conditions. They do not guarantee performance of the supplied product in other formulations or experiments. Mouse and ex vivo patient-sample results do not establish clinical safety or efficacy. PL41 lipid is supplied separately from DSPG, helper lipids and RNA.
Yijia Li, Ting Yang, Xiyue Zhang et al. In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites. Nature Materials (2026). DOI: 10.1038/s41563-026-02769-2. Primary paper.
Structure: main Fig. 2h; Supplementary synthesis pp. 21–22 and Fig. S7. Formulation: Supplementary Table S1. Lead comparisons: Fig. 2 and Supplementary Fig. S6.
Molecular weight is prefilled from the product record. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 7.4062 mL | 1.4812 mL | 0.7406 mL |
| 25 mg | 18.5155 mL | 3.7031 mL | 1.8516 mL |
| 50 mg | 37.0310 mL | 7.4062 mL | 3.7031 mL |
| 100 mg | 74.0620 mL | 14.8124 mL | 7.4062 mL |
| 250 mg | 185.1550 mL | 37.0310 mL | 18.5155 mL |
Contact our team with the catalog number and requested quantity.
Request batch-specific storage, stability and handling instructions. The paper does not establish a shelf life for the supplied neat lipid or its solutions.
DC Chemicals supplies the lipid only. Use laboratory controls appropriate for a research compound; request current safety and quality documentation before use.